Gilead’s Kite will collaborate with BBG Advanced Therapies, a subsidiary of nonprofit BioBridge Global, to deploy BBG’s Mobile Leukapheresis Center (MLC) across Texas — enabling more patients to access Kite’s CAR-T cell therapies.
The MLC is a first‑of‑its‑kind platform that brings the initial T-cell collection step directly to patients in their communities, aligning with Kite’s strategy to scale access to cell therapy and reach more eligible people closer to home.
Kite’s two approved therapies, Tecartus and Yescarta, are both CD19-directed genetically modified autologous T-cell immunotherapies. Tecartus is approved for relapsed/refractory B-cell precursor acute lymphoblastic leukemia and relapsed/refractory mantle cell lymphoma. Yescarta is approved for relapsed/refractory large B-cell lymphoma and relapsed/refractory follicular lymphoma
The Texas deployment of the mobile leukapheresis will serve as a proof‑of‑concept model for additional markets, signaling how mobile collection infrastructure can support the continued growth of cell and gene therapies while maintaining the quality and consistency.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!